US Transcatheter Embolization and Occlusion Device Market to Grow at Just over Nine Percent Per Year Through 2016

US Transcatheter Embolization and Occlusion Device Market to Grow at Just over Nine Percent Per Year Through 2016

<0> Decision Resources GroupChristopher Comfort, 781-993-2597orMillennium Research GroupAlex Jablokow, 617-599-8613 </0>

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States transcatheter embolization and occlusion (TEO) device market will grow strongly through 2016, supported by an aging US population and a trend away from traditional surgical procedures and toward minimally invasive procedures, with particular growth in aneurysm treatment. The US TEO market will grow at an average annual rate of just over nine percent through 2016.

Minimally invasive procedures have been growing rapidly in the United States in both the peripheral vascular and interventional neuroradiology indications. The uptake has been particularly strong in the treatment of aneurysms. The standard treatment for aneurysms has long been surgical clipping, but as of 2011 a significant majority of aneurysm procedures used endovascular techniques such as coiling, stent-assisted coiling, treatment with liquid embolics and treatment with flow-diverting devices.

Interventional neuroradiology (INR) flow-diverting devices, in fact, are the fastest-growing segment among transcatheter embolization and occlusion devices in the US. These devices could represent a universal solution for the most difficult to treat aneurysm cases, such as fusiform, wide-neck, giant and multilobar aneurysms. Though they cost more per unit, they tend to be cost-effective overall when compared to alternative treatments for giant or wide-necked aneurysms, such as stent-assisted coiling. Currently, only ev3 (a Covidien company) has a flow-diverting device on the US market, the Pipeline Embolization Device, typically called just the Pipeline.

“Physicians are excited to add INR flow-diverting devices to their toolbox,” said MRG Analyst Sean Messenger. “In our interviews with them, they cited the advantages of aneurysm shrinkage, which does not happen with coils, shorter procedure times, and procedure simplicity. The willingness of interventional radiologists to try new technologies will lead to strong uptake of these devices. By penetrating into the endovascular aneurysm treatment market and increasing the overall treatable patient population this segment of the market will grow at an average annual rate of almost 35 percent.”

Currently, ev3 is the only company with an INR flow-diverting device on the US market, and this advantage is expected to persist through 2016. The lack of competition has allowed ev3 to use a staggered rollout for the PED, supported by extensive training and certification.

Millennium Research Group’s report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for INR embolization coils, INR coiling-assist devices, INR flow-diverting devices, PV embolization coils, PV plugs, embolization particles, liquid embolics and TEO accessory devices sold in the United States.

Millennium Research Group (), a Decision Resources Group company (), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.